ESC Professional Premium Access

Optimal risk factor therapy in high risk patients

Event: ESC Congress 2022
Topic: Risk Factors and Prevention
Session type: Abstract Sessions
Date: 28 August 2022
Time: 11:30 - 12:30

Congress Session

6 presentations in this session

Effect of evolocumab versus placebo added to standard lipid-lowering therapy on fasting and post fat load lipids and lipoproteins in familial dysbetalipoproteinemia

Speaker: Ms B. Heidemann (Utrecht, NL)

Effects of canagliflozin on cardiovascular and kidney outcomes and mortality in primary and secondary cardiovascular prevention: pooled analysis from the CANVAS program and CREDENCE trial

Speaker: Doctor A. Sharma (Montreal, CA)

Icosapent Ethyl diminishes CVD risk in smokers: REDUCE-IT smoking

Speaker: Professor M. Miller (Philadelphia, US)

Evolocumab treatment reduces carotid intima-media thickness in paediatric patients with heterozygous familial hypercholesterolaemia

Speaker: Doctor A. Wiegman (Amsterdam, NL)

The effect of achieving LDL-C <1.8 mmol/L to prevent the first atherosclerotic cardiovascular events in the primary prevention settings of severe heterozygous familial hypercholesterolemia

Speaker: Doctor S. Funabashi (Osaka, JP)

Clinical consequences of the lipid-lowering treatment in patients with acute coronary syndrome: real-world retrospective study (LipidACS study)

Speaker: Doctor J. Alarcon (Donostia, ES)

6 speakers from this session

Ms Britt Heidemann

University Medical Center Utrecht, Utrecht (Netherlands (The))
0 follower

Doctor Abhinav Sharma

McGill University Health Centre, Montreal (Canada)
1 presentation
0 follower

Professor Michael Miller

Corporal Michael J Crescenz VA Medical Center, Philadelphia (United States of America)
0 follower

Doctor Albert Wiegman

Amsterdam University Medical Centre, Amsterdam (Netherlands (The))
0 follower

Doctor Sayaka Funabashi

National Cerebral and Cardiovascular Center Hospital, Osaka (Japan)
1 follower

Doctor Jose Antonio Alarcon

Donostia University Hospital, Donostia (Spain)
0 follower

This platform is supported by

logo Novo Nordisk